Randomized trial demonstrates improved progression-free and overall survival with pembrolizumab in advanced cervical cancer, indicating a potent first-line treatment combination.
Progression-free and overall survival were significantly longer with pembrolizumab than with placebo among patients with persistent, recurrent, or metastatic cervical cancer who were also receiving chemotherapy with or without bevacizumab. (Funded by Merck Sharp and Dohme; KEYNOTE-826 ClinicalTrials.gov number, NCT03635567.).
No takes yet. Share an insight, caveat, or question.
Colombo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: